Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure

Nov 14, 2018

Overview : Trial Reference Velazquez EJ, Morrow DA, DeVore AD, et al., for the PIONEER-HF Investigators. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2018 Nov 11 [epub ahead of print]. Abstract | Full Text   Expert Comment Pablo Avanzas. Professor of Medicine, Universidad de... more

Effect of Loading Dose of Atorvastatin Prior to Planned PCI: The SECURE-PCI Randomized Clinical Trial

Apr 18, 2018

Overview : Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome. The SECURE-PCI Randomized Clinical Trial   Trial References Patti G, Cannon CP, Murphy SA, et al. Clinical benefit of statin... more

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout

Mar 22, 2018

Overview : Trial Reference White WB, Saag KG, Becker MA, et al; CARES Investigators. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018 Mar 12. doi: 10.1056/NEJMoa1710895. [Epub ahead of print] Abstract | Full Text   Expert Comment... more

: PARADIGM-HF. Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Oct 15, 2014

Overview : The the novel agent LCZ696 (Novartis) that has effects both within and beyond the renin-angiotensin system, was tested against of the ACE inhibitor enalapril, showing fewer HF hospitalizations and mortality from cardiovascular causes, acccording a phase 3 trial PARADIGM-HF. In... more

RELAX TRIAL: Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial

Jul 17, 2014

Overview : RELAX-AHF was an international, double-blind, placebo-controlled trial, enrolling patients admitted to hospital for acute heart failure who were randomly assigned (1:1) via a central randomisation scheme blocked by study centre to standard care plus 48-h intravenous infusions of placebo or... more

PARAMOUNT: Prospective Comparison of ARNI with ARB on Management of Heart Failure with Preserved Ejection Fraction

Jul 17, 2014

Overview : The result showed that levels of NT-proBNP dropped 23% (p=0.005) over 12 weeks but only by 15% (p=0.20) over 36 weeks among those receiving LCZ696 compared with valsartan. LCZ696 was effective for the primary [natriuretic-peptide] end point in every single... more